Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

  • Showing results for a modified search because your search retrieved no results.
1.

Drug Class Review: Pegylated Interferons for Chronic Hepatitis C Infection: Final Report [Internet].

Chou R, Carson S, Chan BKS, Care B.

Portland (OR): Oregon Health & Science University; 2007 May.

2.

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J.

J Viral Hepat. 2007 Apr;14(4):228-38.

PMID:
17381714
3.

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group.

J Viral Hepat. 2006 Dec;13(12):811-20.

PMID:
17109680
5.

HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.

Helbling B, Jochum W, Stamenic I, Knöpfli M, Cerny A, Borovicka J, Gonvers JJ, Wilhelmi M, Dinges S, Müllhaupt B, Esteban A, Meyer-Wyss B, Renner EL; Swiss Association for the Study of the Liver (SASL).

J Viral Hepat. 2006 Nov;13(11):762-9.

PMID:
17052276
6.

Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.

Mathew A, Peiffer LP, Rhoades K, McGarrity T.

Dig Dis Sci. 2006 Nov;51(11):1956-61. Epub 2006 Sep 27.

PMID:
17004124
7.

A simple and valid tool distinguished efficacy from effectiveness studies.

Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS.

J Clin Epidemiol. 2006 Oct;59(10):1040-8. Epub 2006 Aug 4.

PMID:
16980143
8.

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.

Brandão C, Barone A, Carrilho F, Silva A, Patelli M, Caramori C, Focaccia R, Pereira L, Pedroso M, Tatsch F, Pessoa M; Pegasys Brazilian Study Group.

J Viral Hepat. 2006 Aug;13(8):552-9.

PMID:
16901286
9.

Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States.

Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, Margolis HS.

Gastroenterology. 2006 Aug;131(2):478-84.

PMID:
16890602
10.

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group.

Gastroenterology. 2006 Aug;131(2):451-60. Erratum in: Gastroenterology. 2006 Oct;131(4):1363.

PMID:
16890599
11.
12.

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.

Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL; Swiss Association for the Study of the Liver (SASL).

J Viral Hepat. 2006 Jul;13(7):457-65.

PMID:
16792539
13.

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, Bordens R, Cullen C, Harvey J, Laughlin M.

J Hepatol. 2006 Aug;45(2):204-13. Epub 2006 Apr 18.

PMID:
16780997
14.

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ.

Ann Intern Med. 2006 May 16;144(10):705-14.

PMID:
16702586
15.
16.

Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.

Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R.

J Viral Hepat. 2006 May;13(5):316-21.

PMID:
16637862
17.

Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Santin M, Shaw E, Garcia MJ, Delejido A, de Castro ER, Rota R, Altés J, Baguena F, Valero S, Sala M, Casanova A; HCV/HIV-01 Study Team.

AIDS Res Hum Retroviruses. 2006 Apr;22(4):315-20.

PMID:
16623633
18.

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.

Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T; Nonresponder Retreatment Group.

Gastroenterology. 2006 Apr;130(4):1098-106.

PMID:
16618404
19.

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S.

Gastroenterology. 2006 Apr;130(4):1086-97.

PMID:
16618403

Supplemental Content

Support Center